ANADROL-50 (oxymetholone)
DIAMOND BLACKFAN ANEMIA·+2
MEDA PHARMACEUT
Indication
Hypoplastic anemia
Hypoplastic anemia is a hematologic disorder characterized by significantly reduced production of red blood cells due to bone marrow hypoplasia, occurring either as an isolated erythroid failure or as part of broader trilineage marrow suppression. Read more about Hypoplastic anemia
2 drugs 2 manufacturers
Drugs that treat it
Common Hypoplastic anemia therapies.
ANADROL-50 (oxymetholone)
DIAMOND BLACKFAN ANEMIA·+2
Viatris Specialty
Filter & compare in the drug finder →Opens the drug finder with Hypoplastic anemia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHypoplastic anemia is a hematologic disorder characterized by significantly reduced production of red blood cells due to bone marrow hypoplasia, occurring either as an isolated erythroid failure or as part of broader trilineage marrow suppression.
The condition affects the hematopoietic system in both pediatric and adult populations and can arise from congenital genetic defects, immune-mediated destruction of hematopoietic precursors, or secondary exposures to toxic agents and medications.
Pathophysiologically, it is defined by a hypocellular bone marrow with diminished erythroid precursors and replacement of hematopoietic tissue by fat, leading clinically to peripheral reticulocytopenia, normocytic or macrocytic anemia, fatigue, pallor, and cardiovascular strain.
When accompanied by multi-lineage hypoplasia, affected individuals may also manifest concurrent leukopenia and thrombocytopenia, predisposing them to recurrent infections and abnormal bleeding.
- nih.gov
Hypoplastic anemia is a hematologic disorder characterized by significantly reduced production of red blood cells due to bone marrow hypoplasia, occurring either as an isolated erythroid failure or as part of broader trilineage marrow suppression The condition affects the hematopoietic system in both pediatric and adult populations and can arise from congenital genetic defects, immune-mediated destruction of hematopoietic precursors, or secondary exposures to toxic agents and medications Pathoph...
- nih.gov
Hypoplastic anemia is a hematologic disorder characterized by significantly reduced production of red blood cells due to bone marrow hypoplasia, occurring either as an isolated erythroid failure or as part of broader trilineage marrow suppression
- nih.gov
The condition affects the hematopoietic system in both pediatric and adult populations and can arise from congenital genetic defects, immune-mediated destruction of hematopoietic precursors, or secondary exposures to toxic agents and medications When accompanied by multi-lineage hypoplasia, affected individuals may also manifest concurrent leukopenia and thrombocytopenia, predisposing them to recurrent infections and abnormal bleeding
- nih.gov
Pathophysiologically, it is defined by a hypocellular bone marrow with diminished erythroid precursors and replacement of hematopoietic tissue by fat, leading clinically to peripheral reticulocytopenia, normocytic or macrocytic anemia, fatigue, pallor, and cardiovascular strain
- nih.gov
When accompanied by multi-lineage hypoplasia, affected individuals may also manifest concurrent leukopenia and thrombocytopenia, predisposing them to recurrent infections and abnormal bleeding
Personalize your experience
Follow Hypoplastic anemia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.